TB-500 TGA testing found no detectable TB-500 in three tested products whose labels listed it. The findings concern specific unapproved products from one brand, identified in Australia. They do not establish a market-wide failure rate.
For someone considering a prescription, the question is practical: who knows what was prescribed, who dispensed it, and who can investigate a problem?
What TB-500 TGA testing found
As of November 5, 2026, the day this article was written, Australia's Therapeutic Goods Administration (TGA), its medicines regulator, has published a November 5 safety advisory. Its table lists four product labels:
| Label listed in the Australian advisory | Finding in tested material |
|---|---|
| BPC 157 & TB 500 10 mg | TB-500 was not detected |
| KLOW 80 mg | TB-500 was not detected |
| BARBIE KLOW 100 mg | TB-500 was not detected |
| Retatrutide 10 mg | Less retatrutide than labeled, with substantial differences between samples |
All four are products of one brand, which the advisory names; they were identified when the TGA assisted New South Wales police with an investigation. The names and amounts in the table are that brand's labels, not a finding about other products sold under similar names. The advisory does not give a total count of individual samples. TGA says retatrutide is still undergoing clinical trials in humans, has not been approved by the TGA or any comparable international regulator, and that any retatrutide product obtained outside a clinical trial could be counterfeit.
The regulator told buyers of the affected brand to stop using its products, take remaining product to a pharmacy for disposal, speak to a health professional about any health concerns, and report suspected side effects to the TGA. It also urged consumers more broadly not to use unapproved peptide products, particularly ones in unmarked vials, bought online or obtained from overseas, and its Chief Medical Adviser warned of a serious risk of a major allergic response, including anaphylaxis. The linked advisory identifies the brand and shows packaging photographs.
What the prescription route changes
A prescription adds people and records to the decision. An identifiable prescriber assesses the person's history, medicines, allergies, and reason for seeking treatment. A licensed U.S. compounding pharmacy, which prepares medication for an individual prescription, dispenses it.
The records connect what was prescribed with what was dispensed and to whom. There is a pharmacist to answer product questions and a clinician to assess symptoms. A suspected problem can be investigated using those records, including the preparation's batch, the group made together.
Those are concrete differences from an anonymous purchase. They do not guarantee that a medicine will never have a quality problem. The FDA's compounding questions and answers explain that poor compounding practices can cause serious quality problems, such as contamination or too much or too little active ingredient, which can lead to serious injury and death.
For someone considering Wolverine through Promise, the relevant difference is that documented care relationship. An online product name alone cannot supply it. The gray-market peptides guide explains the broader distinction between a seller's listing and prescribed care.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
Peptide label accuracy involves several separate checks
Peptides are short chains of amino acids, the building blocks of proteins. Testing needs to establish which chain is present before its amount means much.
In a 2012 analysis in Drug Testing and Analysis, Esposito and colleagues identified a thymosin beta-4 fragment in material sold as TB-500. A fragment is a short piece of a larger molecule. They used chromatography, which separates a sample's components, and mass spectrometry, which helps identify molecules by their mass.
That paper identified material in a particular product. It did not certify everything later sold under the same name.
The same distinction applies to BPC-157. Its appearance on a blend label cannot establish that every listed ingredient is present in the stated amount. Each ingredient needs its own identity and amount assessed.
| Check | Plain question |
|---|---|
| Identity | Is the named molecule present? |
| Amount | How much of that molecule is there? |
| Purity | What other chemical material accompanies it? |
| Sterility | Are living germs detected? |
| Endotoxin | Is there bacterial material that can trigger a reaction? |
A 2024 test-purchase study in the Journal of Medical Internet Research illustrates why these questions stay separate. Ashraf and colleagues found bacterial residue in online semaglutide samples even though testing found no living germs. That was a separate study of another compound; it does not describe the Australian samples.
The endotoxin explainer covers that bacterial residue. A chemical identity result cannot stand in for every contamination test.
What these results do not mean
Missing an ingredient, containing the wrong amount, and causing a particular illness are different findings. A label mismatch alone cannot identify the cause of someone's symptoms. It also cannot show how often a problem happens across a whole market.
Nor does confirming a vial's contents establish that its ingredient helps an injury. Product testing and treatment studies answer different questions.
As of November 5, 2026, the day this article was written, an October 27 orthopedics review reinforces that distinction. Orthopedics concerns bones, joints, muscles, and related tissues. The authors searched studies through June 2026 and found no controlled human evidence establishing orthopedic treatment benefits for these peptides. A review brings existing studies together; it is not a new treatment trial.
The TB-500 research update separates the fragment from its larger parent molecule and explains the animal findings. Neither a positive animal experiment nor a correct ingredient label supplies a human recovery timeline.
Where the separate U.S. policy discussion stands
As of November 5, 2026, the day this article was written, HHS, the Department of Health and Human Services, has published an October 30 notice announcing a draft, nonbinding peptide-compounding policy. It describes when the department doesn't intend to take action while ingredient-list rules are developed; the HHS policy guide explains its conditions.
TB-500's FDA status
TB-500 is coming soon to Promise as a compounded medication, which is different from an FDA-approved product. The formulation Promise will offer is not FDA-approved. FDA explains that compounded medicines do not undergo its review for safety, effectiveness, or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
What to watch next
The TGA says New South Wales police inquiries are ongoing. Useful follow-up details would include which batches were affected, how many samples were examined, and what the tests could detect. Those details would clarify the investigation's reach. A market-wide failure rate would require a study designed to represent that market.
A person reporting a suspected problem can provide label photographs, batch information, where the product came from, and what happened after use. FDA MedWatch instructions accept reports from consumers as well as health professionals, including suspected counterfeit products and quality problems. A consumer can submit a report themselves.
In prescribed care, the clinician and dispensing pharmacy also have records to work from. That gives a concern somewhere specific to go and people responsible for responding.
